A series of previous and ongoing work by Peter Lobie’s group have described the potent cancer driving properties of autocrine/paracrine GH using breast cancer cell line MCF7 and its mutant variants - MCF7-hGH and MCF-MUT, with constitutive expression or absence of transgenic hGH respectively[109,125]. The gene discussed is GH1; the disease is breast carcinoma.